Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders.

Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol (2010) 2.69

The mutator pathway is a feature of immunodeficiency-related lymphomas. Proc Natl Acad Sci U S A (2004) 1.04

Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★). Am J Transplant (2011) 1.04

Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases. Haematologica (2011) 0.98

Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation (2008) 0.95

Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep (2013) 0.89

Hepatitis C virus and non-Hodgkin's lymphoma: Findings from the Swiss HIV Cohort Study. Br J Cancer (2006) 0.86

Anaplastic lymphoma kinase (ALK) protein expressing lymphoma after liver transplantation: case report and literature review. J Clin Pathol (2002) 0.85

Rare presentation of post-transplant lymphoproliferative disorder isolated to gastroesophageal junction. World J Gastrointest Oncol (2013) 0.80

Isolated post-transplantation lymphoproliferative disease involving the breast and axilla as peripheral T-cell lymphoma. Korean J Radiol (2013) 0.80

Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far? Clin Dev Immunol (2013) 0.79

Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders. Oncotarget (2016) 0.79

Incidence, risk factors and outcomes of de novo malignancies post liver transplantation. World J Hepatol (2016) 0.78

Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management. Transplant Direct (2015) 0.75

Extranodal Natural Killer/T-Cell Lymphoma of the Nasal Type with Skin Metastases. Case Rep Oncol (2016) 0.75

Treatment of post-transplantation lymphoproliferative disorders after kidney transplant with rituximab and conversion to m-TOR inhibitor. Colomb Med (Cali) (2016) 0.75

Lymph Node Flow Cytometry as a Prompt Recognition of Ultra Early Onset PTLD: A Successful Case of Rituximab Treatment. Case Rep Hematol (2015) 0.75

p52 Activation in monomorphic B-cell posttransplant lymphoproliferative disorder/diffuse large B-cell lymphoma without BAFF-R expression. Am J Pathol (2011) 0.75

Monomorphic Post-transplant Lymphoproliferative Disorder After Kidney Transplantation and Hematopoietic Stem Cell Transplantation: Clinicopathological Characteristics, Treatments and Prognostic Factors. Indian J Hematol Blood Transfus (2017) 0.75

Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients. Exp Hematol Oncol (2017) 0.75

Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood (1995) 16.81

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia (2003) 13.41

Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet (2001) 5.82

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology (1999) 5.55

Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol (2001) 3.64

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet (1998) 3.62

Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest (2007) 3.58

Liver fibrosis in overweight patients. Gastroenterology (2000) 3.56

CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans. Proc Natl Acad Sci U S A (2001) 3.54

Treatment of older patients with mantle-cell lymphoma. N Engl J Med (2012) 3.46

Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol (2005) 3.34

Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut (2008) 2.97

Transforming growth factor beta1, in the presence of granulocyte/macrophage colony-stimulating factor and interleukin 4, induces differentiation of human peripheral blood monocytes into dendritic Langerhans cells. J Exp Med (1998) 2.75

Misspecified regression model for the subdistribution hazard of a competing risk. Stat Med (2007) 2.65

[Recording expulsive forces during childbirth using intercostal muscle electromyogram: a pilot study]. Gynecol Obstet Fertil (2005) 2.62

Adult T-biphenotypic acute leukaemia: clinical and biological features and outcome. Br J Haematol (2003) 2.36

Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS (1996) 2.28

Plasma levels of thrombomodulin in pulmonary hypertension. Am J Med (1996) 2.10

TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol (1999) 2.05

Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med (2008) 2.05

Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood (2001) 1.98

Caspase activation is required for terminal erythroid differentiation. J Exp Med (2001) 1.97

Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia (2006) 1.88

Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant (2010) 1.86

Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia (2001) 1.82

Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia (2004) 1.81

Management of focal nodular hyperplasia and hepatocellular adenoma in young women: a series of 41 patients with clinical, radiological, and pathological correlations. Hepatology (1995) 1.78

Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum (1999) 1.77

Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia (2006) 1.76

De novo kidney graft tumors: results from a multicentric retrospective national study. Am J Transplant (2012) 1.74

Individual smallest detectable difference in bone mineral density measurements. J Bone Miner Res (1999) 1.74

Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia (2006) 1.72

Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant (2009) 1.65

ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia (2007) 1.64

A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients. Leukemia (2004) 1.63

Pacemaker infective endocarditis. Am J Cardiol (1998) 1.62

Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936. Leukemia (2006) 1.62

Functional analysis of the TAN-1 gene, a human homolog of Drosophila notch. Cold Spring Harb Symp Quant Biol (1994) 1.61

Hydroxyapatite-coated versus grit-blasted femoral stems. a prospective, randomised study using EBRA-FCA. J Bone Joint Surg Br (2001) 1.60

Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther (2014) 1.60

EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia (2012) 1.60

Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis (2005) 1.59

Description of a novel FR1 IgH PCR strategy and its comparison with three other strategies for the detection of clonality in B cell malignancies. Leukemia (1995) 1.58

Evidence of HTLV-II infection in Guinea, West Africa. J Acquir Immune Defic Syndr (1993) 1.57

Common bile duct stricture as a late complication of upper abdominal radiotherapy. J Hepatol (1994) 1.56

Video-thoracoscopic pericardial window in the diagnosis and treatment of pericardial effusions. Am J Cardiol (1998) 1.55

Human herpesvirus 8 (HHV8) transmission and related morbidity in organ recipients. Am J Transplant (2012) 1.53

Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema. J Allergy Clin Immunol (2000) 1.53

World Health Organization grade 'a' motility and zona-binding test accurately predict IVF outcome for mild male factor and unexplained infertilities. Hum Reprod (2005) 1.52

The role of HLA genes in familial spondyloarthropathy: a comprehensive study of 70 multiplex families. Ann Rheum Dis (2002) 1.51

ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol (2013) 1.51

In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndrome-related lymphomas: correlation with tumor morphology and primary site. Blood (1993) 1.50

Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol (1998) 1.49

Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol (2001) 1.47

Hepatitis virus infections in heart transplant recipients: epidemiology, natural history, characteristics, and impact on survival. Gastroenterology (2000) 1.47

Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM). Bone Marrow Transplant (2000) 1.44

HIV-associated non-Hodgkin's lymphomas: clinical characteristics and outcome. The experience of the French Registry of HIV-associated tumors. Ann Oncol (1991) 1.44

Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency. Am J Pathol (1993) 1.44

Incidence of spasm at the site of previous successful transluminal coronary angioplasty: effect of ergometrine maleate in consecutive patients. Br Heart J (1986) 1.43

Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood (1998) 1.42

Machine perfusion in clinical trials: the preservation solution bias. Transpl Int (2011) 1.40

Minimal change nephrotic syndrome and classical Hodgkin's lymphoma: report of 21 cases and review of the literature. Kidney Int (2006) 1.40

A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer (1977) 1.40

Primary follicular lymphoma of the gastrointestinal tract: a study of 25 cases and a literature review. Ann Oncol (2003) 1.40

A human minor histocompatibility antigen which appears to segregate with the major histocompatibility complex. Transplantation (1994) 1.39

The significance of increased 111indium platelet accumulation at post-angioplasty sites. Clin Radiol (1996) 1.39

Repeat measurements of nuchal translucency at 11-14 weeks of gestation: when do we need them? Ultrasound Obstet Gynecol (2013) 1.39

Dynamic cardiomyoplasty: effect of discontinuing latissimus dorsi muscle stimulation on left ventricular systolic and diastolic performance and exercise capacity. J Am Coll Cardiol (1995) 1.39

Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation. Aliment Pharmacol Ther (2007) 1.38

Follow-up of controls participating in case-control studies for cancer risk factors. Int J Epidemiol (1990) 1.38

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. Br J Cancer (2009) 1.37

Evidence for a cytotoxic T-lymphocyte alveolitis in human immunodeficiency virus-infected patients. AIDS (1988) 1.37

The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia (2011) 1.37

Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology (1998) 1.37

Absence of graft-versus-leukemia (GVL) effect by leucocytes transfused: a prospective randomized trial in acute myeloid leukemia (AML) patients. Br J Haematol (1991) 1.37

Interleukin-6 gene expression in Castleman's disease. Blood (1991) 1.37

Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood (1995) 1.36

Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol (2001) 1.36

Impaired antibody affinity maturation process characterizes a subset of patients with common variable immunodeficiency. J Immunol (2000) 1.35

Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Société Française de Greffe de Moëlle (SFGM). Br J Haematol (1997) 1.33

Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2. Leukemia (2013) 1.31

The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. Blood (1998) 1.31

Modulated expression of notch1 during thymocyte development. Blood (1996) 1.31

In vivo production of interleukin-10 by malignant cells in AIDS lymphomas. Eur J Immunol (1992) 1.31

Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care Med (2011) 1.30

Fatigue in patients with chronic hepatitis C. J Viral Hepat (2002) 1.30

Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis (2009) 1.30

Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha. Ann Rheum Dis (2003) 1.30

Declining autopsy rate in a French hospital: physician's attitudes to the autopsy and use of autopsy material in research publications. Arch Pathol Lab Med (2000) 1.28

A different ontogenesis for chronic lymphocytic leukemia cases carrying stereotyped antigen receptors: molecular and computational evidence. Leukemia (2009) 1.27

The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation. Leukemia (2010) 1.26

Non-Hodgkin lymphoma in Uganda: a case-control study. AIDS (2000) 1.25

Persistence of T8+/HNK-1+ suppressor lymphocytes in the blood of long-term surviving patients after allogeneic bone marrow transplantation. J Immunol (1986) 1.25

Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B.M.T. of 117 cases. Br J Haematol (1988) 1.23

Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am (2000) 1.22